MADRIGAL PHARMACEUTICALS, INC. — Form 10-Q
Filed November 3, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 5/100
What the filing says
William J. Sibold (CEO) and Mardi C. Dier (CFO) signed standard Sarbanes-Oxley certifications on November 3, 2026 for the Q3 2026 10-Q period ended September 30, 2026, attesting to the accuracy of financial statements, effectiveness of disclosure controls, and absence of known material misstatements or fraud. No changes to internal controls or material weaknesses were disclosed.
Why this rating
Routine Sarbanes-Oxley compliance filing. Standard executive certifications required by law; no substantive business developments, financial results, or control changes disclosed in text.
See more from November 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.